1. Home
  2. EFSI vs ADAG Comparison

EFSI vs ADAG Comparison

Compare EFSI & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eagle Financial Services Inc

EFSI

Eagle Financial Services Inc

N/A

Current Price

$45.97

Market Cap

252.1M

Sector

Finance

ML Signal

N/A

Logo Adagene Inc.

ADAG

Adagene Inc.

N/A

Current Price

$2.17

Market Cap

222.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EFSI
ADAG
Founded
1881
2011
Country
United States
China
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
252.1M
222.2M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
EFSI
ADAG
Price
$45.97
$2.17
Analyst Decision
Hold
Strong Buy
Analyst Count
3
6
Target Price
★ $47.00
$9.91
AVG Volume (30 Days)
38.2K
★ 225.9K
Earning Date
10-22-2026
08-12-2026
Dividend Yield
★ 2.70%
N/A
EPS Growth
N/A
N/A
EPS
★ 2.49
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.52
$129.59
P/E Ratio
$18.39
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$31.44
$1.50
52 Week High
$48.17
$4.85

Technical Indicators

Market Signals
Indicator
EFSI
ADAG
Relative Strength Index (RSI) 52.77 42.05
Support Level $45.07 N/A
Resistance Level $47.73 $2.78
Average True Range (ATR) 1.11 0.25
MACD -0.06 -0.01
Stochastic Oscillator 40.09 31.76

Price Performance

Historical Comparison
EFSI
ADAG

About EFSI Eagle Financial Services Inc

Eagle Financial Services Inc is a locally owned and managed financial institution. It offers retail and commercial banking services, including demand, savings and time deposits and consumer, mortgage, and commercial loans. It also offers telephone banking, internet banking, and mobile banking to its customers. The Company has three reportable operating segments, Community Banking, Marine Lending and Wealth Management. It generates a majority of its revenue from the Community Banking segment.

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

Share on Social Networks: